Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients
Top Cited Papers
Open Access
- 23 July 2008
- journal article
- clinical trial
- Published by Springer Science and Business Media LLC in Breast Cancer Research and Treatment
- Vol. 115 (2), 359-363
- https://doi.org/10.1007/s10549-008-0128-9
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast CancerJournal of Clinical Oncology, 2008
- Preoperative Therapy in Invasive Breast Cancer: Pathologic Assessment and Systemic Therapy Issues in Operable DiseaseJournal of Clinical Oncology, 2008
- BRCA1 Mutation and Young Age Predict Fast Breast Cancer Growth in the Dutch, United Kingdom, and Canadian Magnetic Resonance Imaging Screening TrialsClinical Cancer Research, 2007
- Clinical Outcomes of Breast Cancer in Carriers ofBRCA1andBRCA2MutationsThe New England Journal of Medicine, 2007
- BRCA1 Downregulation Leads to Premature Inactivation of Spindle Checkpoint and Confers Paclitaxel ResistanceCell Cycle, 2006
- The Role of BRCA1 in the Cellular Response to ChemotherapyJNCI Journal of the National Cancer Institute, 2004
- Estrogen Receptor Status in BRCA1 - and BRCA2 -Related Breast CancerClinical Cancer Research, 2004
- A combined analysis of outcome following breast cancer: differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatmentBreast Cancer Research, 2003
- The Breast Cancer Susceptibility Gene BRCA1 Is Required for Subnuclear Assembly of Rad51 and Survival following Treatment with the DNA Cross-linking Agent CisplatinOnline Journal of Public Health Informatics, 2000
- Multifactorial Analysis of Differences Between Sporadic Breast Cancers and Cancers Involving BRCA1 and BRCA2 MutationsJNCI Journal of the National Cancer Institute, 1998